IGFBP7 Human

Insulin-Like Growth Factor Binding Protein-7 Human Recombinant
Cat. No.
BT17129
Source
Escherichia Coli.
Synonyms
Insulin-like growth factor-binding protein 7, IBP-7, IGF-binding protein 7, IGFBP-7, IGFBP-rP1, MAC25 protein, PGI2-stimulating factor, Prostacyclin-stimulating factor, Tumor-derived adhesion factor, TAF, IGFBP7, MAC25, PSF, AGM, FSTL2, RAMSVPS, IGFBP-7v, IGFBPRP1.
Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Purity
Greater than 97.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Usage

THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Shipped with Ice Packs
In Stock
Quick Inquiry

Description

Recombinant Human IGFBP7 produced in E.coli cells is a non-glycosylated, homodimeric protein containing 2x256 amino acid chains and having a molecular mass of 26.4kDa.
The IGFBP-7 is purified by proprietary chromatographic techniques.

Product Specs

Introduction
Insulin-like Growth Factor-Binding Protein 7 (IGFBP7), a member of the IGFBP family, is characterized by its cysteine-rich nature and conserved cysteine residues. These proteins share common structural features, including an IGFBP domain, a Kazal-like domain, and an Ig-like C2-type domain. IGFBP7 exhibits widespread expression in various normal human tissues. However, its expression is frequently downregulated in cancer cell lines derived from the prostate, breast, colon, and lung. Functionally, IGFBP7 plays a crucial role in skeletal myogenesis by binding to IGF and inhibiting IGF-induced differentiation of skeletal myoblasts. Notably, it does not interfere with IGF-induced proliferation. Furthermore, IGFBP7 demonstrates growth-suppressive effects and inhibits colony formation in prostate and breast cancer cell lines through an IGF-independent mechanism. This mechanism involves inducing a delay in the G1 phase of the cell cycle, ultimately leading to increased apoptosis.
Description
Recombinant Human IGFBP7, produced in E.coli cells, is a non-glycosylated protein with a homodimeric structure. It consists of two polypeptide chains, each containing 256 amino acids, resulting in a molecular mass of 26.4kDa. The purification of IGFBP-7 is achieved through proprietary chromatographic techniques.
Physical Appearance
Sterile Filtered White lyophilized powder.
Formulation
The IGFBP7 was lyophilized from a 0.2µm filtered concentrated solution in 20mM Tris-HCl, pH 8.5 and 150mM NaCl.
Solubility
To reconstitute the lyophilized IGFBP-7, it is recommended to dissolve it in sterile 20mM acetic acid (AcOH) at a concentration of at least 100µg/ml. This solution can then be further diluted into other aqueous solutions.
Stability
Lyophilized IGFBP7 remains stable at room temperature for up to 3 weeks; however, it is recommended to store it desiccated below -18°C. After reconstitution, IGFBP-7 should be stored at 4°C for a period of 2-7 days. For long-term storage, it is advisable to store it below -18°C. To enhance stability during long-term storage, the addition of a carrier protein (0.1% HSA or BSA) is recommended. It is important to avoid repeated freeze-thaw cycles.
Purity
The purity of IGFBP7 is greater than 97.0%, as determined by the following methods: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
Synonyms
Insulin-like growth factor-binding protein 7, IBP-7, IGF-binding protein 7, IGFBP-7, IGFBP-rP1, MAC25 protein, PGI2-stimulating factor, Prostacyclin-stimulating factor, Tumor-derived adhesion factor, TAF, IGFBP7, MAC25, PSF, AGM, FSTL2, RAMSVPS, IGFBP-7v, IGFBPRP1.
Source
Escherichia Coli.
Amino Acid Sequence
SSSDTCGPCE PASCPPLPPL GCLLGETRDA CGCCPMCARG EGEPCGGGGA GRGYCAPGME CVKSRKRRKG KAGAAAGGPG VSGVCVCKSR YPVCGSDGTT YPSGCQLRAA SQRAESRGEK AITQVSKGTC EQGPSIVTPP KDIWNVTGAQ VYLSCEVIGI PTPVLIWNKV KRGHYGVQRT ELLPGDRDNL AIQTRGGPEK HEVTGWVLVS PLSKEDAGEY ECHASNSQGQ ASASAKITVV DALHEIPVKK GEGAEL.

Product Science Overview

Introduction

Insulin-Like Growth Factor Binding Protein-7 (IGFBP7) is a member of the IGFBP family, which plays a crucial role in modulating the activity of insulin-like growth factors (IGFs). IGFBP7 is a secreted protein that binds IGF-1, insulin, vascular endothelial growth factor A (VEGFA), and activin A . It is involved in various physiological and pathological processes, including cell proliferation, apoptosis, migration, and tumor progression .

Structural Characteristics

IGFBP7 is part of a family of low-affinity IGF-binding proteins known as IGFBP-related proteins . Unlike other members of the IGFBP family (IGFBP1-6), IGFBP7 binds IGFs with lower affinity . This protein also stimulates cell adhesion and has been implicated in several cancers .

Expression Patterns

IGFBP7 is expressed in various tissues and has been linked to different physiological and pathological conditions. For instance, its expression is associated with poor prognosis in multiple myeloma but may protect against bone disease . The expression of IGFBP7 is regulated by methylation, and high levels of IGFBP7 are associated with adverse survival outcomes in multiple myeloma patients .

Functional Roles

IGFBP7 has multifaceted roles in both normal physiology and disease states:

  1. Cell Proliferation and Apoptosis: IGFBP7 regulates cell proliferation and apoptosis, playing a significant role in maintaining cellular homeostasis .
  2. Tumor Progression: IGFBP7 is involved in tumor progression and has been identified as a potential tumor suppressor in hepatocellular carcinoma (HCC) . It regulates cellular proliferation, senescence, and angiogenesis .
  3. Renal Diseases: IGFBP7 has important regulatory effects in renal diseases, including acute kidney injury .
  4. Reproductive Processes: IGFBP7 is also involved in reproductive processes, influencing various aspects of fertility and reproductive health .
Mechanistic Pathways

The regulatory effects of IGFBP7 are mediated through various mechanistic pathways. It antagonizes bone morphogenetic proteins and is involved in the tumor propagation of both solid and hematological malignancies . Additionally, IGFBP7 overcomes activin A-induced osteoblast suppression and promotes osteogenesis .

Clinical Significance

The clinical significance of IGFBP7 is evident in its role as a prognostic marker and potential therapeutic target. High expression of IGFBP7 is associated with adverse chromosomal aberrations and higher myeloma cell proliferation . Conversely, higher IGFBP7 expression is linked to a lower probability of myeloma bone disease .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

Related Products

IGFBP 1 Human
Insulin-Like Growth Factor Binding Protein-1 Human Recombinant
Cat. No.
BT16250
Source
Mouse myeloma cell line, NS0.
IGFBP 4 Human
Insulin-Like Growth Factor Binding Protein-4 Human
Cat. No.
BT16328
Source
HEK293 cells.
IGFBP 5 Human
Insulin-Like Growth Factor Binding Protein-5 Human Recombinant
Cat. No.
BT16415
Source
Escherichia Coli.
IGFBP3 Human
IGFBP3 Human Recombinant
Cat. No.
BT16669
Source
Escherichia Coli.
THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.